A recent study7 also looking at potential biomarkers of DCIS progression, identified the genes FGF2, GAS1, and SFRP1 as being markers of in situ progression, suggesting their downregulation contributed to the invasiveness of epithelial cells. The gene discussed is FGF2; the disease is ductal breast carcinoma in situ.